nach oben

Osteoporosis International

Erschienen in:

08.08.2016 | Review

Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease

verfasst von: A. D. Dede, G. Trovas, E. Chronopoulos, I. K. Triantafyllopoulos, I. Dontas, N. Papaioannou, S. Tournis

Erschienen in: Osteoporosis International | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

Summary

Thalassemia-associated osteoporosis constitutes a major complication in patients with thalassemia. This review presents the existing studies on the treatment of thalassemia-associated osteoporosis and discusses the management of this debilitating complication. A brief presentation of the disease characteristics and pathogenetic mechanisms is also provided.

The life expectancy of patients with thalassemia has increased markedly in recent years resulting in the aging of the population and the emergence of new comorbidities. The majority of patients with thalassemia have low bone mineral density and experience lifelong fracture rates as high as 71 %. The pathogenesis of thalassemia-associated osteoporosis (TAO) is multifactorial with anemia and iron overload playing crucial role in its development. Data concerning the prevention and treatment of TAO are extremely limited. We performed a literature research in Pubmed and Scopus to identify interventional studies evaluating the effects of various agents on TAO. Seventeen studies were retrieved. We present the results of these studies as well as a brief overview of TAO including presentation, pathogenesis, and management. Most of the studies identified are of poor quality, are not randomized controlled, and include small number of participants. There are no data concerning effects on fracture rates. Bisphosphonates are the most widely studied agents and among them zoledronic acid is the most well studied. Hormone replacement treatment (HRT) shows beneficial but small effects. Denosumab and strontium ranelate have each been evaluated in only a single study, while there are no data about the effects of anabolic agents. Given the increased life expectancy and the increase in fracture rates with age, more data about the management of TAO are warranted. Moreover, due to the need for lifelong management starting at young age, careful treatment plans which may include sequential treatment may often be required. However, currently, there are no relevant data available.

Weatherall DJ (1997) The thalassaemias. BMJ 314(7095):1675–1678PubMedPubMedCentralCrossRef

Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Origa R, Piga A, Romeo MA, Zhao H, Cnaan A (2005) Survival and complications in thalassemia. Ann N Y Acad Sci 1054:40–47PubMedCrossRef

Modell B, Darlison M (2008) Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 86(6):480–487PubMedPubMedCentralCrossRef

Fung EB, Harmatz P, Milet M, Ballas SK, De Castro L, Hagar W, Owen W, Olivieri N, Smith-Whitley K, Darbari D, Wang W, Vichinsky E (2007) Multi-Center Study of Iron Overload Research Group. Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: a report from the multi-center study of iron overload. Am J Hematol 82(4):255–265PubMedCrossRef

Voskaridou E, Ladis V, Kattamis A, Hassapopoulou E, Economou M, Kourakli A, Maragkos K, Kontogianni K, Lafioniatis S, Vrettou E, Koutsouka F, Papadakis A, Mihos A, Eftihiadis E, Farmaki K, Papageorgiou O, Tapaki G, Maili P, Theohari M, Drosou M, Kartasis Z, Aggelaki M, Basileiadi A, Adamopoulos I, Lafiatis I, Galanopoulos A, Xanthopoulidis G, Dimitriadou E, Mprimi A, Stamatopoulou M, Haile ED, Tsironi M, Anastasiadis A, Kalmanti M, Papadopoulou M, Panori E, Dimoxenou P, Tsirka A, Georgakopoulos D, Drandrakis P, Dionisopoulou D, Ntalamaga A, Davros I, Karagiorga M, Group GHS (2012) A national registry of haemoglobinopathies in Greece: deducted demographics, trends in mortality and affected births. Ann Hematol 91(9):1451–1458PubMedCrossRef

Baldini M, Forti S, Marcon A, Ulivieri FM, Orsatti A, Tampieri B, Airaghi L, Zanaboni L, Cappellini MD (2010) Endocrine and bone disease in appropriately treated adult patients with beta-thalassemia major. Ann Hematol 89(12):1207–1213PubMedCrossRef

Vogiatzi MG, Macklin EA, Fung EB, Cheung AM, Vichinsky E, Olivieri N, Kirby M, Kwiatkowski JL, Cunningham M, Holm IA, Lane J, Schneider R, Fleisher M, Grady RW, Peterson CC, Giardina PJ, Network TCR (2009) Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res 24(3):543–557PubMedCrossRef

Exarchou E, Politou C, Vretou E, Pasparakis D, Madessis G, Caramerou A (1984) Fractures and epiphyseal deformities in beta-thalassemia. Clin Orthop Relat Res 189:229–233

Finsterbush A, Farber I, Mogle P, Goldfarb A (1985) Fracture patterns in thalassemia. Clin Orthop Relat Res 192:132–136

10.

Dines DM, Canale VC, Arnold WD (1976) Fractures in thalassemia. J Bone Joint Surg Am 58(5):662–666PubMedCrossRef

11.

Fung EB, Harmatz PR, Milet M, Coates TD, Thompson AA, Ranalli M, Mignaca R, Scher C, Giardina P, Robertson S, Neumayr L, Vichinsky EP, Multi-Center Iron Overload Study Group (2008) Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia. Bone 43(1):162–168PubMedPubMedCentralCrossRef

12.

Vogiatzi MG, Macklin EA, Fung EB, Vichinsky E, Olivieri N, Kwiatkowski J, Cohen A, Neufeld E, Giardina PJ (2006) Prevalence of fractures among the thalassemia syndromes in North America. Bone 38(4):571–575PubMedCrossRef

13.

Ruggiero L, De Sanctis V (1998) Multicentre study on prevalence of fractures in transfusion-dependent thalassaemic patients. J Pediatr Endocrinol Metab 11(Suppl 3):773–778PubMed

14.

Sutipornpalangkul W, Janechetsadatham Y, Siritanaratkul N, Harnroongroj T (2010) Prevalence of fractures among Thais with thalassaemia syndromes. Singap Med J 51(10):817–821

15.

Engkakul P, Mahachoklertwattana P, Jaovisidha S, Chuansumrit A, Poomthavorn P, Chitrapazt N, Chuncharunee S (2013) Unrecognized vertebral fractures in adolescents and young adults with thalassemia syndromes. J Pediatr Hematol Oncol 35(3):212–217PubMedCrossRef

16.

Bielinski BK, Darbyshire PJ, Mathers L, Crabtree NJ, Kirk JM, Stirling HF, Shaw NJ (2003) Impact of disordered puberty on bone density in beta-thalassaemia major. Br J Haematol 120(2):353–358PubMedCrossRef

17.

Wong P, Fuller PJ, Gillespie MT, Kartsogiannis V, Kerr PG, Doery JC, Paul E, Bowden DK, Strauss BJ, Milat F (2014) Thalassemia bone disease: a 19-year longitudinal analysis. J Bone Miner Res 29(11):2468–2473PubMedCrossRef

18.

Voskaridou E, Kyrtsonis MC, Terpos E, Skordili M, Theodoropoulos I, Bergele A, Diamanti E, Kalovidouris A, Loutradi A, Loukopoulos D (2001) Bone resorption is increased in young adults with thalassaemia major. Br J Haematol 112(1):36–41PubMedCrossRef

19.

Angelopoulos NG, Goula A, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, Konstandelou E, Tolis G (2007) Markers of bone metabolism in eugonadal female patients with beta-thalassemia major. Pediatr Hematol Oncol 24(7):481–491PubMedCrossRef

20.

Morabito N, Gaudio A, Lasco A, Atteritano M, Pizzoleo MA, Cincotta M, La Rosa M, Guarino R, Meo A, Frisina N (2004) Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. J Bone Miner Res 19(5):722–727PubMedCrossRef

21.

Mahachoklertwattana P, Sirikulchayanonta V, Chuansumrit A, Karnsombat P, Choubtum L, Sriphrapradang A, Domrongkitchaiporn S, Sirisriro R, Rajatanavin R (2003) Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron-associated focal osteomalacia. J Clin Endocrinol Metab 88(8):3966–3972PubMedCrossRef

22.

Domrongkitchaiporn S, Sirikulchayanonta V, Angchaisuksiri P, Stitchantrakul W, Kanokkantapong C, Rajatanavin R (2003) Abnormalities in bone mineral density and bone histology in thalassemia. J Bone Miner Res 18(9):1682–1688PubMedCrossRef

23.

Bordat C, Constans A, Bouet O, Blanc I, Trubert CL, Girot R, Cournot G (1993) Iron distribution in thalassemic bone by energy-loss spectroscopy and electron spectroscopic imaging. Calcif Tissue Int 53(1):29–37PubMedCrossRef

24.

Chatterjee R, Shah FT, Davis BA, Byers M, Sooranna D, Bajoria R, Pringle J, Porter JB (2012) Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome. Br J Haematol 159(4):462–471PubMedCrossRef

25.

Rioja L, Girot R, Garabédian M, Cournot-Witmer G (1990) Bone disease in children with homozygous beta-thalassemia. Bone Miner 8(1):69–86PubMedCrossRef

26.

Voskaridou E, Christoulas D, Plata E, Bratengeier C, Anastasilakis AD, Komninaka V, Kaliontzi D, Gkotzamanidou M, Polyzos SA, Dimopoulou M, Terpos E (2012) High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density. Horm Metab Res 44(12):909–913PubMedCrossRef

27.

Voskaridou E, Christoulas D, Xirakia C, Varvagiannis K, Boutsikas G, Bilalis A, Kastritis E, Papatheodorou A, Terpos E (2009) Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. Haematologica 94(5):725–758PubMedPubMedCentralCrossRef

28.

Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E (2012) Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women—the six-month effect of risedronate and teriparatide. Osteoporos Int 23(3):1171–1176. doi:10.1007/s00198-010-1525-6 PubMedCrossRef

29.

Memon AR, Butler JS, O’Riordan MV, Guerin E, Dimitrov BD, Harty JA (2013) Comparison of serum Dkk1 (Dickkopf-1) and bone mineral density in patients on bisphosphonate treatment vs no treatment. J Clin Densitom 16(1):118–124. doi:10.1016/j.jocd.2012.07.003 PubMedCrossRef

30.

van Lierop AH, Moester MJ, Hamdy NA, Papapoulos SE (2014) Serum Dickkopf 1 levels in sclerostin deficiency. J Clin Endocrinol Metab 99(2):E252–E256PubMedCrossRef

31.

Centis F, Tabellini L, Lucarelli G, Buffi O, Tonucci P, Persini B, Annibali M, Emiliani R, Iliescu A, Rapa S, Rossi R, Ma L, Angelucci E, Schrier SL (2000) The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with beta-thalassemia major. Blood 96(10):3624–3629PubMed

32.

Cazzola M, De Stefano P, Ponchio L, et al. (1995) Relationship between transfusion regimen and suppression of erythropoiesis in beta-thalassaemia major. Br J Haematol 89(3):473–478PubMedCrossRef

33.

Arnett TR (2010) Acidosis, hypoxia and bone. Arch Biochem Biophys 503(1):103–109PubMedCrossRef

34.

Lu H, Lian L, Shi D, Zhao H, Dai Y (2015) Hepcidin promotes osteogenic differentiation through the bone morphogenetic protein 2/small mothers against decapentaplegic and mitogen-activated protein kinase/P38 signaling pathways in mesenchymal stem cells. Mol Med Rep 11(1):143–150PubMedCrossRef

35.

Shen GS, Yang Q, Jian JL, Zhao GY, Liu LL, Wang X, Zhang W, Huang X, Xu YJ (2014) Hepcidin1 knockout mice display defects in bone microarchitecture and changes of bone formation markers. Calcif Tissue Int 94(6):632–639PubMedCrossRef

36.

Hiram-Bab S, Liron T, Deshet-Unger N, et al. (2015) Erythropoietin directly stimulates osteoclast precursors and induces bone loss. FASEB J 29(5):1890–1900PubMedCrossRef

37.

Yang Q, Jian J, Abramson SB, Huang X (2011) Inhibitory effects of iron on bone morphogenetic protein 2-induced osteoblastogenesis. J Bone Miner Res 26(6):1188–1196PubMedCrossRef

38.

Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR (2004) Thalassemia Clinical Research Network. Complications of beta-thalassemia major in North America. Blood 104(1):34–39PubMedCrossRef

39.

Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A, Prescott E, Hoffbrand AV, Wonke B (1998) High prevalence of low bone mass in thalassaemia major. Br J Haematol 103(4):911–915PubMedCrossRef

40.

Waung JA, Bassett JH, Williams GR (2012) Thyroid hormone metabolism in skeletal development and adult bone maintenance. Trends Endocrinol Metab 23(4):155–162PubMedCrossRef

41.

Angelopoulos NG, Goula A, Rombopoulos G, Kaltzidou V, Katounda E, Kaltsas D, Tolis G (2006) Hypoparathyroidism in transfusion-dependent patients with beta-thalassemia. J Bone Miner Metab 24(2):138–145PubMedCrossRef

42.

Dede AD, Tournis S, Dontas I, Trovas G (2014) Type 2 diabetes mellitus and fracture risk. Metabolism 63(12):1480–1490PubMedCrossRef

43.

Scacchi M, Danesi L, Cattaneo A, Valassi E, Pecori Giraldi F, Argento C, D’Angelo E, Mirra N, Carnelli V, Zanaboni L, Tampieri B, Cappellini MD, Cavagnini F (2008) Bone demineralization in adult thalassaemic patients: contribution of GH and IGF-I at different skeletal sites. Clin Endocrinol 69(2):202–207CrossRef

44.

Sadeghi-Bojd S, Hashemi M, Karimi M (2008) Renal tubular function in patients with beta-thalassaemia major in Zahedan, southeast Iran. Singap Med J 49(5):410–412

45.

Ponticelli C, Musallam KM, Cianciulli P, Cappellini MD (2010) Renal complications in transfusion-dependent beta thalassaemia. Blood Rev 24(6):239–244PubMedCrossRef

46.

Quinn CT, Johnson VL, Kim HY, Trachtenberg F, Vogiatzi MG, Kwiatkowski JL, Neufeld EJ, Fung E, Oliveri N, Kirby M, Giardina PJ, Thalassemia Clinical Research Network (2011) Renal dysfunction in patients with thalassaemia. Br J Haematol 153(1):111–117PubMedPubMedCentralCrossRef

47.

Baldan A, Giusti A, Bosi C, Malaventura C, Musso M, Forni GL, Volpato S, Zuliani G, Borgna-Pignatti C (2015) Klotho, a new marker for osteoporosis and muscle strength in β-thalassemia major. Blood Cells Mol Dis 55(4):396–401PubMedCrossRef

48.

Baldini M, Ulivieri FM, Forti S, Serafino S, Seghezzi S, Marcon A, Giarda F, Messina C, Cassinerio E, Aubry-Rozier B, Hans D, Cappellini MD (2014) Spine bone texture assessed by trabecular bone score (TBS) to evaluate bone health in thalassemia major. Calcif Tissue Int 95(6):540–546PubMedCrossRef

49.

Wong P, Fuller PJ, Gillespie MT, Kartsogiannis V, Strauss BJ, Bowden D, Milat F (2013) Thalassemia bone disease: the association between nephrolithiasis, bone mineral density and fractures. Osteoporos Int 24(7):1965–1971PubMedCrossRef

50.

Chan YL, Pang LM, Chik KW, Cheng JC, Li CK (2002) Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia. Pediatr Radiol 32(7):492–497PubMedCrossRef

51.

Olivieri NF, Koren G, Harris J, Khattak S, Freedman MH, Templeton DM, Bailey JD, Reilly BJ (1992) Growth failure and bony changes induced by deferoxamine. Am J Pediatr Hematol Oncol 14(1):48–56PubMedCrossRef

52.

Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V. (2014) Guidelines for the management of transfusion dependent thalassaemia (TDT). 3rd edition. Thalassaemia International Federation; ISBN-13: 978-9963-717-06-4

53.

Naderi M, Sadeghi-Bojd S, Valeshabad AK, Jahantigh A, Alizadeh S, Dorgalaleh A, Tabibian S, Bamedi T (2013) A prospective study of tubular dysfunction in pediatric patients with beta thalassemia major receiving deferasirox. Pediatr Hematol Oncol 30(8):748–754PubMedCrossRef

54.

Wong P, Polkinghorne K, Kerr PG, Doery JC, Gillespie MT, Larmour I, Fuller PJ, Bowden DK, Milat F (2016) Deferasirox at therapeutic doses is associated with dose-dependent hypercalciuria. Bone 85:55–58PubMedCrossRef

55.

Casale M, Citarella S, Filosa A, De Michele E, Palmieri F, Ragozzino A, Amendola G, Pugliese U, Tartaglione I, Della Rocca F, Cinque P, Nobili B, Perrotta S (2014) Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major. Am J Hematol 89(12):1102–1106PubMedCrossRef

56.

Napoli N, Carmina E, Bucchieri S, Sferrazza C, Rini GB, Di Fede G (2006) Low serum levels of 25-hydroxy vitamin D in adults affected by thalassemia major or intermedia. Bone 38(6):888–892PubMedCrossRef

57.

Fung EB, Aguilar C, Micaily I, Haines D, Lal A (2011) Treatment of vitamin D deficiency in transfusion-dependent thalassemia. Am J Hematol 86(10):871–873PubMedCrossRef

58.

Fung EB (2010) Nutritional deficiencies in patients with thalassemia. Ann N Y Acad Sci 1202:188–196PubMedCrossRef

59.

Fung EB, Xu Y, Kwiatkowski JL, Vogiatzi MG, Neufeld E, Olivieri N, Vichinsky EP, Giardina PJ, Thalassemia Clinical Research Network (2010) Relationship between chronic transfusion therapy and body composition in subjects with thalassemia. J Pediatr 157(4):641–647PubMedPubMedCentralCrossRef

60.

Trachtenberg F, Foote D, Martin M, Carson S, Coates T, Beams O, Vega O, Merelles-Pulcini M, Giardina PJ, Kleinert DA, Kwiatkowski J, Thompson AA, Neufeld EJ, Schilling L, Thayalasuthan V, Pakbaz Z, Yamashita R, Thalassemia Clinical Research Network (2010) Pain as an emergent issue in thalassemia. Am J Hematol 85(5):367–370PubMed

61.

Haines D, Martin M, Carson S, Oliveros O, Green S, Coates T, Eile J, Schilling L, Dinu B, Mendoza T, Gerstenberger E, Trachtenberg F, Vichinsky E, Thalassemia Clinical Research Network (2013) Pain in thalassaemia: the effects of age on pain frequency and severity. Br J Haematol 160(5):680–687PubMedCrossRef

62.

Oliveros O, Trachtenberg F, Haines D, Gerstenberger E, Martin M, Carson S, Green S, Calamaras D, Hess P, Yamashita R, Vichinsky E, Thalassemia Clinical Research Network (2013) Pain over time and its effects on life in thalassemia. Am J Hematol 88(11):939–943PubMedCrossRef

63.

Forni GL, Perrotta S, Giusti A, Quarta G, Pitrolo L, Cappellini MD, D’Ascola DG, Borgna Pignatti C, Rigano P, Filosa A, Iolascon G, Nobili B, Baldini M, Rosa A, Pinto V, Palummeri E (2012) Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study. Br J Haematol 158(2):274–282PubMedCrossRef

64.

Otrock ZK, Azar ST, Shamseddeen WA, Habr D, Inati A, Koussa S, Mahfouz RA, Taher AT (2006) Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial. Ann Hematol 85(9):605–609PubMedCrossRef

65.

Voskaridou E, Anagnostopoulos A, Konstantopoulos K, Stoupa E, Spyropoulou E, Kiamouris C, Terpos E (2006) Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica 91(9):1193–1202PubMed

66.

Green ST, Martin MB, Haines D, Carson S, Coates T, Oliveros O, Gerstenberger E, Trachtenberg F, Kwiatkowski JL, Network TCR (2014) Variance of pain prevalence and associated severity during the transfusion cycle of adult thalassaemia patients. Br J Haematol 166(5):797–800PubMedPubMedCentralCrossRef

67.

Angelopoulos NG, Katounda E, Rombopoulos G, Goula A, Kaltzidou V, Kaltsas D, Ioannis P, Tolis G (2006) Evaluation of bone mineral density of the lumbar spine in patients with beta-thalassemia major with dual-energy X-ray absorptiometry and quantitative computed tomography: a comparison study. J Pediatr Hematol Oncol 28(2):73–78PubMedCrossRef

68.

Mylona M, Leotsinides M, Alexandrides T, Zoumbos N, Dimopoulos PA (2005) Comparison of DXA, QCT and trabecular structure in beta-thalassaemia. Eur J Haematol 74(5):430–437PubMedCrossRef

69.

Bansal D, Venkateshwaran S, Khandelwal N, Marwaha RK (2011) Quantitative computed tomography is unreliable for measurement of bone mineral density in inadequately chelated adolescent patients with β-thalassemia major: a case-control study. Pediatr Blood Cancer 56(3):409–412PubMedCrossRef

70.

Argentiero A, Neglia C, Peluso A, di Rosa S, Ferrarese A, Di Tanna G, Caiaffa V, Benvenuto M, Cozma A, Chitano G, Agnello N, Paladini D, Baldi N, Distante A, Piscitelli P (2013) The ability of lumbar spine DXA and phalanx QUS to detect previous fractures in young thalassemic patients with hypogonadism, hypothyroidism, diabetes, and hepatitis-B: a 2-year subgroup analysis from the Taranto Area of Apulia Region. J Pediatr Hematol Oncol 35(6):e260–e264PubMedPubMedCentralCrossRef

71.

Christoforidis A, Perifanis V, Papadopoulou E, Dimitriadou M, Kazantzidou E, Vlachaki E, Tsatra I (2009) Poor correlations between measurements of bone quality by quantitative ultrasound sonography and dual energy X-ray absorptiometry in patients with beta-thalassaemia major. Eur J Haematol 82(1):15–21PubMedCrossRef

72.

Fung EB, Vichinsky EP, Kwiatkowski JL, Huang J, Bachrach LK, Sawyer AJ, Zemel BS (2011) Characterization of low bone mass in young patients with thalassemia by DXA, pQCT and markers of bone turnover. Bone 48(6):1305–1312PubMedPubMedCentralCrossRef

73.

de Sanctis V, Soliman AT, Elsedfy H, Yassin M, Canatan D, Kilinc Y, Sobti P, Skordis N, Karimi M, Raiola G, Galati MC, Bedair E, Fiscina B, El Kholy M, I-CET (International Network on Growth Disorders and Endocrine Complications in Thalassemia) (2013) Osteoporosis in thalassemia major: an update and the I-CET 2013 recommendations for surveillance and treatment. Pediatr Endocrinol Rev 11(2):167–180PubMed

74.

Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR (2011) Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s Health Initiative limited access dataset and meta-analysis. BMJ 342:d2040PubMedPubMedCentralCrossRef

75.

Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A (2007) Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 370(9588):657–666PubMedCrossRef

76.

Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, Bassford T, Beresford SA, Black HR, Blanchette P, Bonds DE, Brunner RL, Brzyski RG, Caan B, Cauley JA, Chlebowski RT, Cummings SR, Granek I, Hays J, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Johnson KC, Judd H, Kotchen JM, Kuller LH, Langer RD, Lasser NL, Limacher MC, Ludlam S, Manson JE, Margolis KL, McGowan J, Ockene JK, O’Sullivan MJ, Phillips L, Prentice RL, Sarto GE, Stefanick ML, Van Horn L, Wactawski-Wende J, Whitlock E, Anderson GL, Assaf AR, Barad D, Women’s Health Initiative Investigators (2006) Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354(7):669–683PubMedCrossRef

77.

Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA (2011) Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 155(12):827–838PubMedCrossRef

78.

Avenell A, Gillespie WJ, Gillespie LD, O’Connell D (2009) Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 15(2):CD000227

79.

Lewis JR, Calver J, Zhu K, Flicker L, Prince RL (2011) Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up. J Bone Miner Res 26(1):35–41PubMedCrossRef

80.

Paik JM, Curhan GC, Sun Q, Rexrode KM, Manson JE, Rimm EB, Taylor EN (2014) Calcium supplement intake and risk of cardiovascular disease in women. Osteoporos Int 25(8):2047–2056PubMedPubMedCentralCrossRef

81.

Fung EB, Kwiatkowski JL, Huang JN, Gildengorin G, King JC, Vichinsky EP (2013) Zinc supplementation improves bone density in patients with thalassemia: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 98(4):960–971PubMedPubMedCentralCrossRef

82.

Wu KH, Tsai FJ, Peng CT (2003) Growth hormone (GH) deficiency in patients with beta-thalassemia major and the efficacy of recombinant GH treatment. Ann Hematol 82(10):637–640PubMedCrossRef

83.

Arcasoy A, Ocal G, Kemahli S, Berberoğlu M, Yildirmak Y, Canatan D, Akçurin S, Akar N, Uysal Z, Adiyaman P, Cetinkaya E (1999) Recombinant human growth hormone treatment in children with thalassemia major. Pediatr Int 41(6):655–661PubMedCrossRef

84.

Sartorio A, Conte G, Conti A, Masala A, Alagna S, Rovasio P, Faglia G (2000) Effects of 12 months rec-GH therapy on bone and collagen turnover and bone mineral density in GH deficient children with thalassaemia major. J Endocrinol Investig 23(6):356–361CrossRef

85.

Mo D, Fleseriu M, Qi R, Jia N, Child CJ, Bouillon R, Hardin DS (2015) Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective observational cohort study. Lancet Diabetes Endocrinol 3(5):331–338PubMedCrossRef

86.

Gilfillan CP, Strauss BJ, Rodda CP, Bowden DK, Kean AM, Obaid M, Crawford BA (2006) A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia. Calcif Tissue Int 79(3):138–144PubMedCrossRef

87.

Perifanis V, Vyzantiadis T, Tziomalos K, Vakalopoulou S, Garipidou V, Athanassiou-Metaxa M, Harsoulis F (2007) Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia. Ann Hematol 86(1):23–30PubMedCrossRef

88.

Leung TF, Chu Y, Lee V, Cheng FW, Leung WK, Shing MM, Li CK (2009) Long-term effects of pamidronate in thalassemic patients with severe bone mineral density deficits. Hemoglobin 33(5):361–369PubMedCrossRef

89.

Skordis N, Ioannou YS, Kyriakou A, Savva SC, Efstathiou E, Savvides I, Christou S (2008) Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major. Pediatr Endocrinol Rev Suppl 1:144–148

90.

Voskaridou E, Terpos E, Spina G, Palermos J, Rahemtulla A, Loutradi A, Loukopoulos D (2003) Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol 123(4):730–737PubMedCrossRef

91.

Patıroğlu T, Torun YA, Kula M, Karakükçü M (2008) Treatment of thalassemia-induced osteoporosis with intermittent pamidronate infusions: two-year follow up. Turk J Hematol 25(2):79–82

92.

Pennisi P, Pizzarelli G, Spina M, Riccobene S, Fiore CE (2003) Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosis. J Bone Miner Metab 21(6):402–408PubMedCrossRef

93.

Morabito N, Lasco A, Gaudio A, Crisafulli A, Di Pietro C, Meo A, Frisina N (2002) Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos Int 13(8):644–649PubMedCrossRef

94.

Shirani F, Iashkari M, Ahmadi AS, Arabi M, Asefi N (2012) Evaluation of alendronate efficacy on bone mineral density in thalassemic patients. Int J Hematol Oncol Stem Cell Res 6(4):20–24

95.

Lasco A, Morabito N, Gaudio A, Buemi M, Wasniewska M, Frisina N (2001) Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major. Osteoporos Int 12(7):570–575PubMedCrossRef

96.

Anapliotou ML, Kastanias IT, Psara P, Evangelou EA, Liparaki M, Dimitriou P (1995) The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches. Clin Endocrinol 42(3):279–287CrossRef

97.

Yassin MA, Soliman AT, De Sanctis V, Abdelrahman MO, Aziz Bedair EM, AbdelGawad M (2014) Effects of the anti-receptor activator of nuclear factor kappa B ligand denusomab on beta thalassemia major-induced osteoporosis. Indian J Endocrinol Metab 18(4):546–551. doi:10.4103/2230-8210.137516 PubMedPubMedCentralCrossRef

98.

Chavassieux P, Meunier PJ, Roux JP, Portero-Muzy N, Pierre M, Chapurlat R (2014) Bone histomorphometry of transiliac paired bone biopsies after 6 or 12 months of treatment with oral strontium ranelate in 387 osteoporotic women: randomized comparison to alendronate. J Bone Miner Res 29(3):618–628PubMedCrossRef

99.

Morabito N, Catalano A, Gaudio A, Morini E, Bruno LM, Basile G, Tsiantouli E, Bellone F, Agostino RM, Piraino B, La Rosa MA, Salpietro C, Lasco A. Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis. J Bone Miner Metab. 2015 24. Epub

100.

Blake GM, Lewiecki EM, Kendler DL, Fogelman I (2007) A review of strontium ranelate and its effect on DXA scans. J Clin Densitom 10(2):113–119PubMedCrossRef

101.

Canatan D, Akar N, Arcasoy A (1995) Effects of calcitonin therapy on osteoporosis in patients with thalassemia. Acta Haematol 93(1):20–24PubMedCrossRef

102.

Tournis S, Dede AD, Savvidis C, Triantafyllopoulos IK, Kattamis A, Papaioannou N (2015) Effects of teriparatide retreatment in a patient with β-thalassemia major. Transfusion 55(12):2905–2910PubMedCrossRef

103.

Trotta A, Corrado A, Cantatore FP (2010) Anabolic therapy of induced osteoporosis in beta-thalassaemia major: case report and literature review. Reumatismo 62(2):119–126PubMed

104.

Hillard TC, Whitcroft SJ, Marsh MS, Ellerington MC, Lees B, Whitehead MI, Stevenson JC (1994) Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss. Osteoporos Int 4(6):341–348PubMedCrossRef

105.

Misra M, Katzman D, Miller KK, Mendes N, Snelgrove D, Russell M, Goldstein MA, Ebrahimi S, Clauss L, Weigel T, Mickley D, Schoenfeld DA, Herzog DB, Klibanski A (2011) Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa. J Bone Miner Res 26(10):2430–2438PubMedPubMedCentralCrossRef

106.

L’hermite M, Simoncini T, Fuller S, Genazzani AR (2008) Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. Maturitas 60(3–4):185–201PubMedCrossRef

107.

Cappellini MD, Poggiali E, Taher AT, Musallam KM (2012) Hypercoagulability in β-thalassemia: a status quo. Expert Rev Hematol 5(5):505–511PubMedCrossRef

108.

Recommendation to restrict the use of Protelos/Osseor (Strontium ranelate), EMA/258269/2013. Accessed at http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/04/news_detail_001774.jsp&mid=WC0b01ac058001d126

109.

Curhan GC, Willett WC, Speizer FE, Spiegelman D, Stampfer MJ (1997) Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 126(7):497–504PubMedCrossRef

110.

Ferrari S, Bianchi ML, Eisman JA, Foldes AJ, Adami S, Wahl DA, Stepan JJ, de Vernejoul MC, Kaufman JM, IOF Committee of Scientific Advisors Working Group on Osteoporosis Pathophysiology (2012) Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int 23(12):2735–2748PubMedCrossRef

111.

Lewiecki EM (2011) Safety of long-term bisphosphonate therapy for the management of osteoporosis. Drugs 71(6):791–814PubMedCrossRef

112.

Lampropoulou-Adamidou K, Tournis S, Triantafyllopoulos IK (2016) Atypical femoral fracture in a beta-thalassemia major patient with previous bisphosphonate use: case report and a review of the literature. J Musculoskelet Neuronal Interact 16(1):75–78PubMed

113.

Giusti A, Barone A, Balocco M, Pinto V, Pilotto A, Forni GL. (2015) Atypical fractures of the femur and bisphosphonate therapy in patients with beta thalassemia-associated osteoporosis: report of three cases [abstract #19]. In 10th Cooley’s Anemia Symposium, New York Academy of Sciences, New York

114.

Leung F, Lau TW, To M, Luk KD, Kung AW. (2009) Atypical femoral diaphyseal and subtrochanteric fractures and their association with bisphosphonates. BMJ Case Rep. 2009. pii: bcr10.2008.1073.

115.

Voskaridou E, Christoulas D, Konstantinidou M, Tsiftsakis E, Alexakos P, Terpos E (2008) Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial. Haematologica 93(10):1588–1590PubMedCrossRef

116.

Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RL, Tan M, Ruzycky ME, Su G, Eastell R (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27(2):243–254PubMedCrossRef

117.

Eriksen EF, Keaveny TM, Gallagher ER, Krege JH (2014) Literature review: the effects of teriparatide therapy at the hip in patients with osteoporosis. Bone 67:246–256PubMedCrossRef

118.

Eastell R, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J, Audran M, Boonen S, Brixen K, Gomes JM, Obermayer-Pietsch B, Avramidis A, Sigurdsson G, Glüer CC (2009) Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res 24(4):726–736PubMedCrossRef

119.

Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386(9999):1147–1155PubMedPubMedCentralCrossRef

120.

Bishop N, Arundel P, Clark E, Dimitri P, Farr J, Jones G, Makitie O, Munns CF, Shaw N, International Society of Clinical Densitometry (2013) Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2013 Pediatric Official Positions. J Clin Densitom 17(2):275–280CrossRef

121.

Eghbali-Fatourechi G (2014) Bisphosphonate therapy in pediatric patients. J Diabetes Metab Disord 13(1):109PubMedPubMedCentralCrossRef

122.

Pietri M, Lucarini S (2007) The orthopaedic treatment of fragility fractures. Clinical Cases in Mineral and Bone Metabolism 4(2):108–116PubMedPubMedCentral

123.

Michelson J, Cohen A (1988) Incidence and treatment of fractures in thalassemia. J Orthop Trauma 2(1):29–32PubMedCrossRef

Titel: Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease
verfasst von: A. D. Dede
G. Trovas
E. Chronopoulos
I. K. Triantafyllopoulos
I. Dontas
N. Papaioannou
S. Tournis
Publikationsdatum: 08.08.2016
Verlag: Springer London
Erschienen in: Osteoporosis International / Ausgabe 12/2016
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-016-3719-z

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

23.04.2024 | Leitsymptom Rückenschmerzen | Nachrichten

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease

Abstract

Summary

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Ärztliche Empathie hilft gegen Rückenschmerzen

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Brustkrebs in der Vorgeschichte macht Gelenkersatz komplikationsträchtiger

Update Orthopädie und Unfallchirurgie

Springer Medizin

Abstract

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2016

The impact of a standardized order set for the management of non-hip fragility fractures in a Fracture Liaison Service

Mice with sclerostin gene deletion are resistant to the severe sublesional bone loss induced by spinal cord injury

Patient-activation and guideline-concordant pharmacological treatment after bone density testing: the PAADRN randomized controlled trial

Health-related quality of life in older people with osteoporotic vertebral fractures: clinically important vs. statistically significant

Skeletal outcomes by peripheral quantitative computed tomography and dual-energy X-ray absorptiometry in adolescent girls with anorexia nervosa

Evaluation of three risk assessment tools in discriminating fracture status among Chinese patients undergoing hemodialysis

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Ärztliche Empathie hilft gegen Rückenschmerzen

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Brustkrebs in der Vorgeschichte macht Gelenkersatz komplikationsträchtiger

Update Orthopädie und Unfallchirurgie